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rain atherosclerosis”was the term historically
used in an attempt to provide a rational explanation for
the progressive cognitive decline observed in many—but
not all—elderly people.The term was derived from the
observation that the vasculature of the brain was dis-
rupted in the elderly, like that of the rest of the organs,
and that many—but not all—demented individuals
showed brain infarcts at postmortem examination.
Despite the fact that Alois Alzheimer published his
description of a demented individual with no significant
underlying vascular pathology 100 years ago,the efforts
to distinguish between vascular and nonvascular demen-
tia were mostly undertaken in the 1970s.
1-3 The impetus
to distinguish between the two types of dementia,
Alzheimer’s disease (AD) and the entity initially termed
multi-infarct dementia (MID) and later on vascular
dementia (VD), had both scientific and pragmatic
underpinning (the change from MID to VD was neces-
sary,since the term MID did not cover the full range of
cerebrovascular pathology).
Reasoning for differentiation 
between AD and VD
The scientific reasoning for the distinction between AD
and VD was based on evidence collected during the
1970s and 1980s,leading investigators to conclude that a
vascular pathology was not the main underlying pathol-
ogy for most demented individuals. First, many
demented individuals had diffuse amyloid deposits or
plaques and neurofibrillary tangles as the predominant
postmortem pathology, with no or minimal vascular
pathology or infarcts.
1 Second, in some of these
demented individuals with predominantly plaques and
tangles,the counts of the cholinergic cells in the nucleus
basalis of Meynert were diminished, as was the activity
of the neurotransmitter acetylcholine in the cortex.
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“B
Advances in epidemiological, clinical, imaging, and neuro-
pathological studies have undermined the clear distinc-
tion between vascular and Alzheimer-type dementia,
which has characterized the last two decades of research
in dementia. A significant degree of overlap between the
two entities was demonstrated in terms of clinical expres-
sion, risk factors, and postmortem brain autopsy. In this
article, we propose mechanisms by which cardiovascular
risk factors might affect the manifestation of Alzheimer’s
disease, suggest possible explanations for the overlap with
vascular dementia, and discuss the implications this might
have on future differential diagnosis and treatment
strategies.
Dialogues Clin Neurosci. 2003;5:7-15.Taken together, these findings convinced researchers
that AD was a unique and discrete disease entity with
well-defined histology (presence of plaques and tangles)
and neurochemistry (cholinergic deficiency),thus lead-
ing a sustainable hypothesis regarding its pathophysiol-
ogy.
9 On the other hand, as VD was conceptualized as
a “matter of strokes large and small,”
10 the Hachinski
Ischemic Score was developed in order to differentiate
it from AD.The scale is based on presence of risk fac-
tors for VD,such as hypertension,history of strokes,and
evidence of associated atherosclerosis,and on the clini-
cal characteristics of strokes (abrupt onset, stepwise
deterioration,fluctuating course,focal neurological signs,
and symptoms).Additional support for a vascular origin
of dementia according to the Hachinski Ischemic Score
were the presence of nocturnal confusion, relative
preservation of personality, depression, somatic com-
plaints, and emotional incontinence.The items making
up the scale reflect the conceptualization of vascular risk
factors as exclusively associated with brain infarcts,
which, in turn, are responsible for the clinical manifes-
tations of MID (and later VD).
The pragmatic reasoning for the distinction between AD
and VD was the assumption in the late 1970s and early
1980s that specific treatments for AD exist.This assump-
tion was based on the apparent finding that increasing
cholinergic activity by pharmacological manipulations
could improve symptoms in demented individuals.
11-13 In
order to increase the likelihood of demonstrating an
effect for drugs enhancing cholinergic activities, it was
believed to be essential to identify patients affected by
a cholinergic deficit, ie, AD patients, and distinguish
them from VD patients,who were not expected to ben-
efit from cholinergic enhancement.
However, since the late 1990s, this distinction has been
challenged by clinical,neuropathological,epidemiolog-
ical, and even therapeutic studies.The following para-
graphs will elaborate on this challenge, attempt to
explain the role of cardiovascular risk factors in the AD
syndrome, and propose possible interactions between
AD and VD.
Evidence for overlap between AD and VD
Clinical and pathological evidence
The traditional characterization of AD (an insidious and
gradual progression with no focal neurological signs) and
VD (an abrupt onset with stepwise progression and focal
neurological signs) was not unequivocally supported by
data.
14-19 Significant numbers of patients were described
who had predominantly brain infarcts, but an AD-like
course,and vice versa.
20Also,the availability of advanced
imaging methods lead to the recognition of diverse neuro-
anatomical vascular brain lesions (thromboembolic
stroke,small lacunar infarcts,and white matter lesions),
whose implication and etiology are still debatable but are
probably the result of hypoperfusion to brain tissue.
21-23 It
was also recognized that many of the infarcts identified
by imaging techniques or at postmortem examination are
silent infarcts,which do not necessarily contribute to clin-
ical expression in terms of focal signs or symptoms or cog-
nitive impairment.Furthermore,for some VD subtypes,
namely subcortical microvascular disease,mild cognitive
impairment (MCI) can precede dementia and thus mimic
the clinical course of AD.
24
Neuropathologically, the seminal “Nun Study,” which
followed 102 elderly nuns to postmortem,demonstrated
that, among those who met neuropathological criteria
for AD,those with brain infarcts had higher prevalence
of clinically expressed dementia than those without
infarcts.
25 Similarly,the complex interaction between AD
and vascular pathology was demonstrated in a 3-year
follow-up study of stroke patients who were not
demented before the stroke.
26 One third of the patients
who developed poststroke dementia were diagnosed as
suffering from AD.
26 Finally,a substantial proportion of
brains who meet neuropathological criteria for AD show
lesions such as cerebral amyloid angiopathy, microvas-
cular degeneration,periventricular white matter lesions,
and other vascular pathology,
27,28 further complicating
the neuropathological distinction between the two dis-
ease entities.
Epidemiologically, it has been demonstrated that indi-
viduals affected by vascular risk factors during midlife
29-42
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Selected abbreviations and acronyms
AD Alzheimer’s disease
AGE advanced glycation end-product
ApoE apolipoprotein E
APP amyloid precursor protein
HDL high-density lipoprotein
IDE insulin-degrading enzyme
MCI mild cognitive impairment
MID multi-infarct dementia
VD vascular dementiaare more likely to manifest dementia associated with AD-
like brain pathology in old age. Hence, it appears that
most of the risk factors for cardiovascular disease,such as
diabetes,hypertension,abnormal plasma cholesterol,high
intake of saturated fat,thromboembolic episodes,high
fibrinogen concentrations, high serum homocysteine,
atrial fibrillation,smoking,alcoholism,atherosclerosis,
and apolipoprotein E4 (ApoE4) allele,are also risk fac-
tors for AD and not exclusively for VD.
Therapeutically,it was recently shown that drugs enhanc-
ing cholinergic activity are as effective in patients suf-
fering from VD as they are in AD patients,
43 hence elim-
inating the pragmatic justification for the distinction.
The simple solution to the challenge brought to the dis-
tinction between AD and VD is to invoke the “mixed
dementia”notion,by which dementia is caused by the
concomitant presence of both AD-like pathology
(plaques and tangles) and infarcts,which contribute to
the manifestation of dementia in a cumulative fashion.
This explanation has much face validity,since both AD
pathology and VD pathology are age-dependent mani-
festations,hence the idea that they converge to manifest
dementia is a plausible one.A corollary explanation is
that the incidence of cardiovascular risk factors,such as
diabetes and hypertension and additional constituents of
the metabolic syndrome (hyperlipidemia,central obe-
sity), progressively increase after the fifth and sixth
decades of life,
44,45 and contribute to a pathway during the
seventh and eighth decades of life leading to VD,which,
together with AD-like pathology,reaches the threshold
for clinical manifestation of dementia.However,the high
prevalence of demented individuals whose neuropatho-
logical examination reveals both AD and VD pathol-
ogy
28,46-48 does not necessarily prove a synergetic rela-
tionship between the two types of lesions to produce
dementia.It is conceivable that either the neurodegen-
erative or the vascular lesions do not contribute to the
clinical manifestation until a certain load of pathology is
reached. Thus, in some patients with cooccurrence of
both types of lesions, one type of lesion could be
regarded as an “innocent bystander.”Indeed,the corre-
lations between clinically diagnosed mixed dementia and
neuropathological examination remain poor.
49
Cardiovascular risk factors
A more interesting hypothesis of heuristic value would
indicate that the risk conferred by the presence of car-
diovascular risk factors,such as diabetes,hypertension,or
hyperlipidemia,toward AD disease is independent of the
risk conferred by the same risk factors toward VD.The
following paragraphs will review this possibility,provide
suggestions for mechanisms by which cardiovascular risk
factors contribute directly to AD pathology,and discuss
possible ways for interaction and overlap between AD
and VD.Finally,treatment and prevention implications
based on the overlap between the two pathologies will be
briefly discussed.
The idea that abnormal lipoprotein metabolism in gen-
eral,and cholesterol in particular,affects the risk for AD
derives from long-term follow-up of cohorts from mid-
dle age into senescence.Some,
38,41 but not all,
50 long-term
follow-up studies have demonstrated a positive rela-
tionship between plasma hypercholesterolemia in
midlife and rates of AD in old age. Furthermore, high
plasma levels of high-density lipoprotein (HDL) cho-
lesterol in midlife were found to be associated with a
greater load of plaques and tangles in some,
51 but not
all,
52 studies.The simple assumption would be that,in the
same way as a high blood level of cholesterol damages
the vascular endothelium in the periphery, it also dam-
ages the brain vasculature,hence increasing the risk for
VD. However, it is also possible that abnormal choles-
terol metabolism has a direct effect on the brain not
mediated by its effect on the cerebral vasculature.This
is supported by data showing that brain cholesterol
metabolism and transfer is at least partly independent
of systemic cholesterol metabolism.The main source of
brain cholesterol is de novo synthesis in the brain itself,
rather than transport from plasma,
53,54 which possesses a
distinct set of lipoproteins.
55,56 Furthermore,it is assumed
that the major role of the apolipoproteins implicated in
AD in the brain is redistribution of cholesterol between
different brain compartments rather than transfer to
and from the plasma.
57
There exist a number of hypotheses explaining the direct
effect of cholesterol on the brain and on brain patholog-
ical processes.The degree of activity of the different amy-
loid precursor proteins (APPs) cleaving enzymes varies
according to the surrounding lipid moiety:environments
richer in cholesterol promote β- and γ-secretase,which
produce insoluble amyloid plaques.Furthermore,β-amy-
loid also acts as a seed for the amyloid plaque in a lipid-
rich membrane.
58 On the other hand,conditions poorer in
cholesterol promote α-secretase activity,which does not
create plaques.
59-61 Hence brain cholesterol metabolism
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9has an independent effect on amyloid plaque formation,
not mediated by vascular pathology, thus potentially
directly contributing to AD pathology.
Interestingly, recent studies have shown a decrease in
AD prevalence among patients treated with cholesterol-
lowering drugs from the statin group.
62,63 Statins are com-
pounds that inhibit HMG CoA (3-hydroxy-3-methyl-
glutaryl coenzyme A) reductase,a enzyme central to the
process of de novo cholesterol synthesis. Studies have
shown that statins lower the risk of developing demen-
tia independently of their effect on plasma lipid levels
63,64
or exposure to other lipid-lowering drugs.
63These results
suggest that statins have properties additional to their
systemic lipid-lowering effect, some of which are prob-
ably associated with central nervous system (CNS) pro-
tection.
65Taken together,these lines of evidence suggest
that, apart from its atherogenic effect, cholesterol is
involved in several metabolic pathways in the brain,
some of which may be relevant to the pathological
process associated with plaque and tangle formation.
The relationship between AD and apolipoprotein E
(ApoE) also indicates a direct role for abnormal lipopro-
tein metabolism on AD pathology that is not mediated
by vascular lesions.ApoE is a protein involved in lipid
transport and has three isoforms:ApoE2,ApoE3, and
ApoE4.
66 The protein’s polymorphism affects hepatic
binding, uptake, and catabolism of chylomicrons, chy-
lomicron remnants,very-low-density lipoprotein choles-
terol,and subspecies of HDL cholesterol.
67 In the brain,
ApoE is a major lipid-binding protein.
68ApoE complex
has a central role in neuronal repair and maintenance
processes,
69 in which ApoE4 is less efficient than ApoE2
and ApoE3.These differences in the efficacy of neuronal
repair will not be expressed clinically in a young healthy
person with an intact brain.However,when a brain dis-
ease such as AD develops, the presence of the ApoE4
isoform reduces repair efficacy, enhancing tissue and
function loss.
68 In agreement with the theories presented
above, some,
70 but not all,
71-76 population-based studies
have shown the association between ApoE4 allele and
AD to be independent of the lipoprotein’s effect on sys-
temic dyslipidemia and atherogenesis.
However,other data support the vascular mechanism in
ApoE pathology,showing that ApoE4 is a risk factor for
dementia with stroke—either VD or AD with stroke.
77
Neuropathological studies of AD brains demonstrated
that ApoE4 frequency is higher in AD brains with some
kind of cerebrovascular pathology.The frequency of the
ApoE4 alleles was six times higher in AD brains with
moderate-to-severe cerebral amyloid angiopathy,when
compared with mild amyloid angiopathy,and the severity
was correlated with ApoE4 load (one versus two alleles).
78
Diabetes,like hypercholesterolemia,is a complex systemic
metabolic disorder,traditionally regarded as a risk factor
for stroke and consequently for VD.
79-81 Diabetic patients
who suffer strokes are at greater risk for subsequent
dementia than nondiabetic individuals who suffer strokes.
82
The association between AD and diabetes is supported by
some,
29,83,84 but not all,
85-88 epidemiological studies.In mid-
dle-aged men followed until old age,for example,there
is an association between diabetes and neuropathological
finding of both AD and VD dementia.
84
Several mechanisms have been invoked to account for
the direct relationship between diabetes and AD.
Hyperglycemia causes high levels of advanced glycation
end-products (AGEs), which have been found in high
concentrations in neuritic plaques and neurofibrillary
tangles.
89AGEs have been shown to cause cross-linkage
of extracellular proteins and promote aggregation of β-
amyloid.
90 Alternatively, insulin at high levels (charac-
teristic of some phases of type 2 diabetes) could be a
competitive substrate for insulin-degrading enzyme
(IDE).This enzyme has been found to be involved in the
degradation of other substrates as well as insulin, amy-
loid being one of them. It is thus conceivable that high
insulin levels cause competitive inhibition of amyloid
degradation,thus leading to less effective dissolution of
seeds for amyloid plaques.
91,92 Also, elevated levels of
blood insulin have been suggested to impair cognitive
performance,
93 leading to the hypothesis that serum
insulin may alter cognitive function by affecting brain
regions rich in insulin receptors, such as the hypothala-
mus,olfactory bulb,and hippocampus.
94-97
Hypertension,like diabetes,has been directly implicated
in AD by epidemiological studies in which midlife
hypertension was associated with greater number of
neurofibrillary tangles and neuritic plaques in the hip-
pocampus and neocortex,and a more pronounced brain
atrophy compared with midlife normotensive individu-
als.
98 Furthermore, the association between midlife
hypertension and AD remained unchanged after con-
trolling for vascular lesions,such as large infarcts or lacu-
nar infarcts.Although hypertension exerts its deleteri-
ous effect through damage to blood vessels of all
calibers and in all end organs by producing ischemia and
infarcts, it is also plausible that hypertension causes
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10more subtle damage to very small blood vessels, which
results in abnormal endothelial permeability and
extravasation of plasma constituents.
99,100 These, in turn,
could interact with amyloid or amyloid precursor to pro-
mote plaque formation.
19 A corollary possibility is that
hypertension-induced vascular lesions,which lead to tis-
sue ischemia, disrupt endothelial integrity.This enables
interaction between plasma constituents or an effect on
amyloid,thus promoting plaque formation.
White matter lesions are an additional phenomenon
linking cardiovascular risk factors and AD pathology.
Cardiovascular risk factors, such as hypertension, dia-
betes,and ischemic heart disease,have been found to be
associated with white matter lesions by leading to a dys-
function of the blood–brain barrier,which,in turn,either
through plasma component extravasation or brain cell
reaction, promotes white matter changes.
101 White mat-
ter lesions have been suggested to be a common finding
in AD and VD,
102 and have the same neuropathological
appearance in the two disorders. It has been hypothe-
sized that subcortical white matter lesions interact with
AD pathology to produce dementia.
102
Irrespective of the mechanism involved,midlife and late-
life hypertension has been demonstrated to be positively
associated with dementia in old age in several,
38,103-108 but
not all,
109-111 population-based studies.
Hyperhomocysteinemia (higher than 14 micromolar),
which reflects folic acid deficiency, has been associated
with increased incidence of coronary artery disease,
stroke,and cancer,
112-114 as well as impaired cognition and
dementia in some
115,116 studies. However, in one study,
117
total levels of homocysteine were associated with silent
brain infarcts and white matter lesions independently of
each other and of other cardiovascular risk factors.The
contribution of hyperhomocysteinemia to dementia
could be thus mediated by periventricular white matter
lesions, which, in their severe form, were found to be
independently associated with cognitive decline at a
three times faster rate than average.
118 Alternatively,
studies supporting the direct effect of homocysteine on
AD pathology have demonstrated that homocysteine
causes neurotoxicity in cultured neurons by activating
N-methyl-D-aspartate (NMDA) receptors
119 or causing
DNA damage and thus triggering apoptosis.
120
Experiments in cell cultures and mouse models of AD
suggest that folic acid deficiency and homocysteine
impair DNA repair in neurons, which exposes them to
oxidative damage induced by amyloid.
121
Finally, in addition to the independent role of promot-
ing AD pathology, all the risk factors presented above
share the ability to promote atherosclerosis.
122This raises
the question of whether atherosclerosis itself is the final
common pathway through which they are involved in
the pathogenesis of AD. Supporting this possibility is a
population-based study of newly diagnosed demented
patients,in which the frequency of AD and VD was cor-
related with the severity of atherosclerosis. The odds
ratio for AD in those with severe atherosclerosis com-
pared with those without was 3.0.This association was
stronger for those affected by atherosclerosis who were
also ApoE4 carriers.
36 An alternative explanation for
these results could be that dementia causes an aggrava-
tion of atherosclerosis by alteration in lifestyle and diet.
Conclusion
The data presented above lend themselves to several
interpretations.It is possible that “pure”neurohistolog-
ical vascular or “pure”plaques and/or tangles dementias
constitute the extreme and rare end of a continuous
process. In fact, a significant proportion of dementia
cases present vascular lesions upon neurohistological
examination—the location,extent,and clinical implica-
tions of which depend on the damaged vessel, and the
insidious formation of plaques and tangles.
27 The cooc-
currence of two pathological processes acting in parallel
damages brain tissue,which,in turn,leads to a threshold
of brain dysfunction viewed as clinical symptoms.
25 It is
thus conceivable that cerebrovascular damage is caused
in individuals affected in midlife by vascular risk factors,
which later joins progressive and age-dependent forma-
tion of amyloid plaques,thus damaging brain tissue and
being expressed as dementia. Conceptually, this would
not be different from other aging processes leading to
organ failure via several,concomitant processes,such as
cardiac failure due to coronary ischemia and valvulopa-
thy,or leading to functional failure,such as visual failure
due to concomitant cataract and retinopathy.
Alternatively, rather than comorbidity of VD and AD-
type dementia, part of the AD pathological pathway
could involve a vascular component in which impair-
ment of blood–brain barrier leads to disruption of selec-
tive permeability (by altering endothelial functioning),
which,in turn,stimulates plaque and tangle formation.
An additional option for the conceptualization of the
role of risk factors discussed above,and of other risk fac-
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11tors in AD, is that AD is a complex, multifactorial dis-
ease.At various points of the pathway towards amyloid
plaque and neurofibrillary tangle formation, different
contributing factors could pose their effect: the lipid
milieu of the neuronal membrane could contribute to
enhancement of APP-cleaving enzymes (β- and γ-secre-
tase) leading to insoluble products; hyperinsulinemia
could compete with amyloid for IDE and thus enable less
dissolution of amyloid,competitive inhibition of amyloid-
degrading enzyme, and promotion of cross-linkage of
extracellular proteins by AGE;and the presence of the
ApoE4 allele could be less effective in neuronal repair
when disease processes exist.Thus,every risk factor dis-
cussed above could contribute to a different phase of
plaque formation or consolidation.Although this theory
provides an opportunity for an integrative conceptual-
ization regarding the role of the various risk factors
involved in the AD pathway, we are aware of the fact
that it is still speculative in nature and demands further
evidence.
Because some of the cardiovascular risk factors are
modifiable,investigating the mechanisms by which they
contribute to AD pathology and the manifestation of
dementia has implications in prevention.This is partic-
ularly interesting, since in other multifactorial diseases,
such as stroke,coronary heart disease,
123 and colon can-
cer,
124 modifiable environmental factors such as diet,
physical activity,and smoking may account for over half
of the variability leading to the disease. Not surprising
therefore are studies demonstrating that physical and
total activity in midlife,
125-127 diet,
40 and mild-to-moderate
alcohol consumption
128 are protective against AD.
However, these data should be seen with caution since
there are not enough prospective studies to set clear
guidelines regarding the medical and nonmedical strate-
gies for dementia prevention or delay. ❏
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